Related Experiment Video

Updated: Jun 8, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

EGFR mutations and lung cancer

Gilda da Cunha Santos1, Frances A Shepherd, Ming Sound Tsao

  • 1Department of Pathology, Princess Margaret Hospital, Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada. gilda.santos@uhn.on.ca

Annual Review of Pathology
|October 5, 2010
PubMed

Insights

Epidermal growth factor receptor (EGFR) mutations are crucial for non-small cell lung cancer (NSCLC) treatment. Identifying EGFR mutations guides the use of targeted therapies, improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is a key transmembrane protein involved in cellular signaling.
  • Over 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, making it a significant therapeutic target.
  • EGFR's cytoplasmic kinase activity is central to its signaling role.

Purpose of the Study:

  • To review the critical role of EGFR mutations in the diagnosis and management of NSCLC.
  • To highlight the importance of mutation testing for personalized NSCLC treatment strategies.
  • To discuss the efficacy of EGFR-targeted therapies.

Main Methods:

  • Review of clinical trials and scientific literature on EGFR mutations in NSCLC.
  • Analysis of the diagnostic and therapeutic implications of EGFR mutation status.
  • Evaluation of the effectiveness of tyrosine kinase inhibitors (TKIs) in mutant EGFR NSCLC.

Main Results:

  • EGFR tyrosine kinase inhibitors (TKIs) show significant clinical activity, especially in patients with activating EGFR mutations.
  • EGFR mutations are present in over 60% of NSCLC cases.
  • Initial therapy with TKIs may be superior to chemotherapy for advanced NSCLC with EGFR mutations.

Conclusions:

  • Mutation testing for EGFR is mandatory for selecting appropriate NSCLC patients for targeted therapy.
  • Clinico-pathologic characteristics alone are insufficient for patient selection.
  • EGFR mutation status is a critical determinant in the management of NSCLC, guiding treatment decisions towards TKIs.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...